j & j eats itself

Well, the plot thickens.

Valeant in mid Dec bought the division that has Retin a from J&J for about $400 mill.

The following is based on the assumption that the cosmetics partner is j&j.

Have j&j been formulating a product to compete with this product in their now sold division?

From what I gather it is predominantly a prescription product. Thus doesn't match the mass market formula.

But it doesn't mean a mass market product with TPM is not better than the prescription product. Less active thus not requiring a prescription and better effect even from the lower dose. Remember the prime problem is with irritation.

J&j having their new product fully funded by selling the superceded product and keeping the competition watchdogs happy.

Looks like an elegant business solution.